Navigation Links
News from Cancer: Disparities in head and neck cancer patients
Date:10/5/2008

A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer. Published in the November 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that earlier diagnosis and greater access to treatment could improve outcomes for these cancers among African Americans and the poor.

A number of studies have examined disparities in cancer survival among different groups to help identify interventions to improve patient outcomes. To investigate factors that impact survival from head and neck cancer, Dr. Leonidas Koniaris and colleagues at the University of Miami School of Medicine reviewed all head and neck cancer cases in Florida between 1998 and 2002. By mining information from the Florida Cancer Data System and the Florida Agency for Health Care Administration dataset, they were able to accumulate data on diagnoses, comorbid conditions, and procedures performed during every hospitalization or outpatient visit among 20,915 head and neck cancer patients during that time.

The review found poorer outcomes were associated with race, poverty, age, gender, tumor site and stage, treatment type, and a history of smoking and alcohol consumption.

Regarding race, the average survival time among Hispanics was 47 months, compared with 40 months among Caucasians and 21 months among African Americans. African American patients were diagnosed at a younger age and presented with more advanced disease compared with Caucasians. For all tumor stages, African American patients had a significantly shorter average survival time than Caucasians, regardless of poverty level. Treatments also differed between these two races: Caucasians were more likely than African Americans to have undergone surgery (45 percent vs. 32 percent), while African Americans were more likely than Caucasians to receive chemotherapy (26 percent vs. 19 percent) and radiation (66 percent vs. 56 percent). However, even among patients who received surgery, African Americans had a shorter survival time than Caucasians.

When assessing socioeconomic status, the investigators found that patients living in communities with poverty levels exceeding 15 percent were diagnosed with head and neck cancer at a significantly younger age, more frequently diagnosed with advanced disease, and had lower average survival was lower across all age groups. Average survival time was significantly shorter in patients from the areas with the highest poverty rates irrespective of what type of therapy was received.

The authors conclude that racial disparities continue to exist in head and neck cancer survival. Socio-economic inequities are also evident in head and neck cancer survival, even when the poor receive treatment for their disease.

"Earlier diagnosis, particularly in those from low socio-economic status groups and amongst African American patients, is needed to improve outcomes," the authors wrote.


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
213-368-8523
American Cancer Society
Source:Eurekalert

Related medicine news :

1. New approach to cancer: Find most tightly controlled genes
2. With Prostate Cancer: Waiting for Symptoms Is Not an Option
3. Fighting Cancer: Historic Anti-Asbestos Legislation Moving Forward With Support of Meso Foundation
4. Stem cells and cancer: Scientists investigate a fine balancing act
5. A new way to fight cancer: the silver shield
6. Patrick Swayzes Diagnosis With Pancreatic Cancer: a Statement From the Pancreatic Cancer Action Network
7. Pancreatic cancer: The smaller the tumor, the better your chances, study shows
8. Mislabeled Supplement Spurred Prostate Cancer: Report
9. Mislabled Supplement Spurred Prostate Cancer: Report
10. NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer:
11. From Hot Flashes to Breast Cancer: ZRT Labs Hormone Testing Catches On As Women Consider Safer, More Natural Options.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg Leyer, the ... Probiotic Association’s Washington DC workshop on November 2nd. The conference was an opportunity ... probiotic dietary supplement regulations. , Dr. Leyer spoke about two main topics ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink Inc ... for connecting the Life Sciences supply chain and ... today announced that Tjoapack has selected TraceLink,s serialization ... customers comply with the rapidly approaching serialization deadlines ... (DSCSA) in 2017 and the EU Falsified Medicines ...
(Date:12/7/2016)... ZIONA SCIENCE PARK , ... biotechnology company Kadimastem (TASE: KDST) announced today the signing of a ... collaboration between the companies. The synergy between the companies will assist ... collaboration as a worldwide leader in innovative treatment for severe diseases ... ...
Breaking Medicine Technology: